Rescue of a mouse model of spinal muscular atrophy with respiratory distress type 1 by AAV9-IGHMBP2 is dose dependent

Monir Shababi, Zhihua Feng, Eric Villalon, Christine Toedebusch, Erkan Y. Osman, Madeline R. Miller, Patricka A. Williams-Simon, Abby Lombardi, Thalia H. Sass, Arleigh K. Atkinson, Michael L. Garcia, Chien Ping Ko, Christian L. Lorson

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Spinal muscular atrophy with respiratory distress type 1 (SMARD1) is an autosomal recessive disease occurring during childhood. The gene responsible for disease development is a ubiquitously expressed protein, IGHMBP2. Mutations in IGHMBP2 result in the loss of α-motor neurons leading to muscle atrophy in the distal limbs accompanied by respiratory complications. Although genetically and clinically distinct, proximal SMA is also caused by the loss of a ubiquitously expressed gene (SMN). Significant preclinical success has been achieved in proximal SMA using viral-based gene replacement strategies. We leveraged the technologies employed in SMA to demonstrate gene replacement efficacy in an SMARD1 animal model. Intracerebroventricular (ICV) injection of single-stranded AAV9 expressing the full-length cDNA of IGHMBP2 in a low dose led to a significant level of rescue in treated SMARD1 animals. Consistent with drastically increased survival, weight gain, and strength, the rescued animals demonstrated a significant improvement in muscle, NMJ, motor neurons, and axonal pathology. In addition, increased levels of IGHMBP2 in lumbar motor neurons verified the efficacy of the virus to transduce the target tissues. Our results indicate that AAV9-based gene replacement is a viable strategy for SMARD1, although dosing effects and potential negative impacts of high dose and ICV injection should be thoroughly investigated.

Original languageEnglish (US)
Pages (from-to)855-866
Number of pages12
JournalMolecular Therapy
Volume24
Issue number5
DOIs
StatePublished - May 1 2016
Externally publishedYes

Fingerprint

Motor Neurons
Genes
Injections
Muscular Atrophy
Viral Genes
Weight Gain
Extremities
Animal Models
Complementary DNA
Pathology
Viruses
Technology
Muscles
Mutation
Spinal muscular atrophy with respiratory distress 1
Proteins

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Rescue of a mouse model of spinal muscular atrophy with respiratory distress type 1 by AAV9-IGHMBP2 is dose dependent. / Shababi, Monir; Feng, Zhihua; Villalon, Eric; Toedebusch, Christine; Osman, Erkan Y.; Miller, Madeline R.; Williams-Simon, Patricka A.; Lombardi, Abby; Sass, Thalia H.; Atkinson, Arleigh K.; Garcia, Michael L.; Ko, Chien Ping; Lorson, Christian L.

In: Molecular Therapy, Vol. 24, No. 5, 01.05.2016, p. 855-866.

Research output: Contribution to journalArticle

Shababi, M, Feng, Z, Villalon, E, Toedebusch, C, Osman, EY, Miller, MR, Williams-Simon, PA, Lombardi, A, Sass, TH, Atkinson, AK, Garcia, ML, Ko, CP & Lorson, CL 2016, 'Rescue of a mouse model of spinal muscular atrophy with respiratory distress type 1 by AAV9-IGHMBP2 is dose dependent', Molecular Therapy, vol. 24, no. 5, pp. 855-866. https://doi.org/10.1038/mt.2016.33
Shababi, Monir ; Feng, Zhihua ; Villalon, Eric ; Toedebusch, Christine ; Osman, Erkan Y. ; Miller, Madeline R. ; Williams-Simon, Patricka A. ; Lombardi, Abby ; Sass, Thalia H. ; Atkinson, Arleigh K. ; Garcia, Michael L. ; Ko, Chien Ping ; Lorson, Christian L. / Rescue of a mouse model of spinal muscular atrophy with respiratory distress type 1 by AAV9-IGHMBP2 is dose dependent. In: Molecular Therapy. 2016 ; Vol. 24, No. 5. pp. 855-866.
@article{048ccd31c5ea4fb884a19d9f628d2fea,
title = "Rescue of a mouse model of spinal muscular atrophy with respiratory distress type 1 by AAV9-IGHMBP2 is dose dependent",
abstract = "Spinal muscular atrophy with respiratory distress type 1 (SMARD1) is an autosomal recessive disease occurring during childhood. The gene responsible for disease development is a ubiquitously expressed protein, IGHMBP2. Mutations in IGHMBP2 result in the loss of α-motor neurons leading to muscle atrophy in the distal limbs accompanied by respiratory complications. Although genetically and clinically distinct, proximal SMA is also caused by the loss of a ubiquitously expressed gene (SMN). Significant preclinical success has been achieved in proximal SMA using viral-based gene replacement strategies. We leveraged the technologies employed in SMA to demonstrate gene replacement efficacy in an SMARD1 animal model. Intracerebroventricular (ICV) injection of single-stranded AAV9 expressing the full-length cDNA of IGHMBP2 in a low dose led to a significant level of rescue in treated SMARD1 animals. Consistent with drastically increased survival, weight gain, and strength, the rescued animals demonstrated a significant improvement in muscle, NMJ, motor neurons, and axonal pathology. In addition, increased levels of IGHMBP2 in lumbar motor neurons verified the efficacy of the virus to transduce the target tissues. Our results indicate that AAV9-based gene replacement is a viable strategy for SMARD1, although dosing effects and potential negative impacts of high dose and ICV injection should be thoroughly investigated.",
author = "Monir Shababi and Zhihua Feng and Eric Villalon and Christine Toedebusch and Osman, {Erkan Y.} and Miller, {Madeline R.} and Williams-Simon, {Patricka A.} and Abby Lombardi and Sass, {Thalia H.} and Atkinson, {Arleigh K.} and Garcia, {Michael L.} and Ko, {Chien Ping} and Lorson, {Christian L.}",
year = "2016",
month = "5",
day = "1",
doi = "10.1038/mt.2016.33",
language = "English (US)",
volume = "24",
pages = "855--866",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Rescue of a mouse model of spinal muscular atrophy with respiratory distress type 1 by AAV9-IGHMBP2 is dose dependent

AU - Shababi, Monir

AU - Feng, Zhihua

AU - Villalon, Eric

AU - Toedebusch, Christine

AU - Osman, Erkan Y.

AU - Miller, Madeline R.

AU - Williams-Simon, Patricka A.

AU - Lombardi, Abby

AU - Sass, Thalia H.

AU - Atkinson, Arleigh K.

AU - Garcia, Michael L.

AU - Ko, Chien Ping

AU - Lorson, Christian L.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Spinal muscular atrophy with respiratory distress type 1 (SMARD1) is an autosomal recessive disease occurring during childhood. The gene responsible for disease development is a ubiquitously expressed protein, IGHMBP2. Mutations in IGHMBP2 result in the loss of α-motor neurons leading to muscle atrophy in the distal limbs accompanied by respiratory complications. Although genetically and clinically distinct, proximal SMA is also caused by the loss of a ubiquitously expressed gene (SMN). Significant preclinical success has been achieved in proximal SMA using viral-based gene replacement strategies. We leveraged the technologies employed in SMA to demonstrate gene replacement efficacy in an SMARD1 animal model. Intracerebroventricular (ICV) injection of single-stranded AAV9 expressing the full-length cDNA of IGHMBP2 in a low dose led to a significant level of rescue in treated SMARD1 animals. Consistent with drastically increased survival, weight gain, and strength, the rescued animals demonstrated a significant improvement in muscle, NMJ, motor neurons, and axonal pathology. In addition, increased levels of IGHMBP2 in lumbar motor neurons verified the efficacy of the virus to transduce the target tissues. Our results indicate that AAV9-based gene replacement is a viable strategy for SMARD1, although dosing effects and potential negative impacts of high dose and ICV injection should be thoroughly investigated.

AB - Spinal muscular atrophy with respiratory distress type 1 (SMARD1) is an autosomal recessive disease occurring during childhood. The gene responsible for disease development is a ubiquitously expressed protein, IGHMBP2. Mutations in IGHMBP2 result in the loss of α-motor neurons leading to muscle atrophy in the distal limbs accompanied by respiratory complications. Although genetically and clinically distinct, proximal SMA is also caused by the loss of a ubiquitously expressed gene (SMN). Significant preclinical success has been achieved in proximal SMA using viral-based gene replacement strategies. We leveraged the technologies employed in SMA to demonstrate gene replacement efficacy in an SMARD1 animal model. Intracerebroventricular (ICV) injection of single-stranded AAV9 expressing the full-length cDNA of IGHMBP2 in a low dose led to a significant level of rescue in treated SMARD1 animals. Consistent with drastically increased survival, weight gain, and strength, the rescued animals demonstrated a significant improvement in muscle, NMJ, motor neurons, and axonal pathology. In addition, increased levels of IGHMBP2 in lumbar motor neurons verified the efficacy of the virus to transduce the target tissues. Our results indicate that AAV9-based gene replacement is a viable strategy for SMARD1, although dosing effects and potential negative impacts of high dose and ICV injection should be thoroughly investigated.

UR - http://www.scopus.com/inward/record.url?scp=84960192546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960192546&partnerID=8YFLogxK

U2 - 10.1038/mt.2016.33

DO - 10.1038/mt.2016.33

M3 - Article

C2 - 26860981

AN - SCOPUS:84960192546

VL - 24

SP - 855

EP - 866

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 5

ER -